Catalyst
Slingshot members are tracking this event:
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KURA |
|
|
||||
Additional Information
The trial is designed to enroll approximately 58 patients and will evaluate tipifarnib as a treatment for patients with lower risk myelodysplastic syndromes. Patient samples will be analyzed for the presence or absence of various biomarkers potentially relevant to the activity of tipifarnib. Additional information about this clinical trial is available at clinicaltrials.gov using the identifier: NCT02779777.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Study, Tipifarnib, Lower Risk Myelodysplastic Syndrome
